Objective: This study investigates salivary gland biopsies in living patients with Parkinson disease (PD).
There is no tissue biopsy test to diagnose Parkinson disease (PD). Many potential tissue biomarkers are being studied, including CSF, [1] [2] [3] saliva, 4 colon, 5 and skin. 6 Currently, a diagnosis is made based on clinical findings, and autopsy studies estimate the clinical diagnostic accuracy for PD ranges from 46% to 90%. [7] [8] [9] [10] [11] While autopsy findings of Lewy bodies in the substantia nigra remains the gold standard for diagnosis, a postmortem survey of Lewy type a-synucleinopathy (LTS) in the peripheral nervous system (PNS) 12 found a rostral caudal gradient from the lower esophagus and submandibular gland to the colon and rectum. 12 In a postmortem study of 28 PD cases, LTS was found in all 28 whole block mounts of the submandibular gland. 13 Needle cores from 17/19 (89.5%) of these postmortem submandibular glands were positive for LTS, 13 suggesting needle core biopsies in living patients with PD may be diagnostic.
As submandibular gland biopsies are used in clinical practice, usually fine-needle aspirations for cancer cell detection but also 16-gauge core needle biopsy, 14 these autopsy findings led to this in vivo proof-of-concept study for submandibular gland biopsies in living patients with PD. As others have found LTS in minor salivary glands, 15, 16 we performed minor salivary gland biopsies as well on the same patients. Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. study, only 15 patients were included. Inclusion criteria included a clinical diagnosis of PD with disease duration $5 years and a clear response to dopaminergic medication. Subjects were excluded if they were unable to sign informed consent due to dementia, had a bleeding diathesis, were taking an anticoagulant, were medically unable to undergo biopsy, or if they had a known salivary gland disorder. On the day of biopsy (both submandibular gland and minor salivary gland biopsies were performed at the same visit and the combined time took ;30 minutes) the patient met with the otolaryngologist (M.L.H., D.G.L.), who fully explained the biopsy procedures and performed the biopsies as outpatient procedures in a standard examination room.
Standard protocol approvals, registrations, and patient consents. All subjects signed written informed consent approved by the Mayo Clinic Institutional Review Board. The title of the consent form was "Salivary Gland Biopsies as a Diagnostic Test for Parkinson's Disease." Approval from the institutional review board, with a new consent form, was obtained when the biopsy needle was changed from 18-gauge to 16-gauge.
Submandibular gland biopsy. A commercially available instrument was used to obtain tissue cores (Max-Core Disposable Core Biopsy Instrument, Bard Medical, Covington, GA). Either an 18-gauge (first 4 patients) or 16-gauge needle was used. The switch to the 16-gauge needle was to increase the amount of tissue obtained during the biopsy. Both the 18-and 16-gauge needles were 10 cm in length, had internal diameters of 1.02 mm and 1.29 mm, and a sample notch of 1.8 cm and 1.9 cm, respectively. Submandibular glands were localized by palpation and biopsies were performed unilaterally (figure 1). Local anesthetic (0.5 mL of lidocaine) was injected into the skin overlying the submandibular gland. This was followed by a 3-to 5-minute waiting period to allow the lidocaine to take effect. The biopsy needle was inserted transcutaneously, parallel (first 4 cases) then perpendicular to the longitudinal axis of the gland, to a depth of ;22 mm. Between 1 and 5 needle core biopsies were performed for each patient. After the procedure, pressure was used briefly to stop bleeding.
Minor salivary gland biopsy. The minor salivary gland biopsies were performed by everting the lower lip and injecting local anesthetic (0.5 mL lidocaine) subcutaneously into the medial aspect a few millimeters below the upper aspect of the lower lip. A few minutes were given for the drug to take effect. A 2-to 3-mm vertical incision was then made in the lip through which between 2 and 5 minor salivary glands were obtained. Minor salivary glands were individually removed and required dissection away from adjoining tissue using forceps and a scissors. One to three dissolvable sutures were used to close the incision site.
The day after the procedure, each patient was contacted by telephone to inquire about adverse events.
Tissue preparation. Tissue from submandibular gland and minor salivary glands were immediately placed in separate single standard plastic cassettes between 2 sponges and immersed in 70 mL of neutral-buffered 10% formalin (Fisher Scientific, Kalamazoo, MI). After 24 hours fixation at 4°C, the tissue cores were dehydrated in alcohols, infiltrated with paraffin, and serial sections cut at 5-7 mm with a rotary microtome. Every section was collected and mounted on a separate slide, beginning with the first appearance of tissue fragments and ending when tissue fragments were no longer visible. Reserving half of the sections in case of possible technical failure, every second section was immunohistochemically stained for phosphorylated a-synuclein using an immunoperoxidase reaction with nickel enhancement followed by a light Neutral Red counterstain. 13 The prior evaluation of several different immunohistochemical methods has been published previously. 17 Proteinase K was found to give not only superior epitope exposure but also may assist with stain specificity by digesting normal, non-aggregated a-synuclein, which has been a confounding factor in some recent studies. 18, 19 The primary antibody was raised against a-synuclein phosphorylated at serine 129 20 and has been demonstrated to be reactive only with the phosphorylated epitope 21 ; this makes it more likely that stained peripheral structures are pathologic, as we have found that normal control subjects never have immunohistochemically positive PNS elements. 12 Adjustment of the original protocol to better suit peripheral tissue and needle cores has been described in detail. 13 RESULTS Fifteen patients with PD were enrolled: 9 female and 6 male, mean age was 68.7 years (range 61-81), and the mean PD disease duration was 11.8 years (range 6-17). Thirteen patients had motor fluctuations. Six were former smokers, having quit at least 15 years prior to the biopsy. Submandibular gland biopsy findings. Submandibular gland tissue core total length and total tissue volume varied (table) . Total core length and total core volume markedly increased when the biopsy method changed to perpendicular rather than parallel needle insertions, more needle insertions, and a larger caliber needle (16-gauge vs 18-gauge).
Initial microscopic examination of the submandibular gland tissue cores showed the variable presence of skin, subcutaneous tissue, striated muscle, and salivary gland tissue. Three of the initial cases did not have any tissue elements consistent with submandibular gland and others had miniscule amounts, ,1.6 mm 2 on greatest cross-sectional area, so the sampling method was expanded (as described above), resulting in a total of 12 cases having identifiable salivary gland tissue. Microscopic assessment for LTS revealed 9 of 12 subjects (75%) with identifiable salivary gland were positive. A characteristic needle core tissue sample is Figure 1 Needle biopsy of the submandibular gland presented ( figure 2A ). Only structures morphologically consistent with nervous tissue were considered to represent a positive biopsy finding (figure 2). Eight of the 9 positive cases had immunoreactive phosphorylated a-synuclein staining in nerve fibers or puncta within submandibular salivary gland tissue while 1 was positive only in the subcutaneous connective tissue of a skin fragment. Positive fibers were most frequently seen within stromal connective tissue of the gland, often within nerve fascicles (figure 2, B and C) but also close to or within the walls of small arteries and arterioles (figure 2D) or just beneath duct epithelium (figure 2E). Less commonly but not infrequently, immunoreactive fibers were seen interweaving among parenchymal serous gland cells ( figure 2F ). Up to 105 stained submandibular gland sections were examined for each subject with a mean positive slide percentage of 23.7% (table) . There were no clinically distinguishable features among the 3 subjects that had negative biopsies. Nonspecific staining (staining that was not in nervous tissue) was present in occasional tissue fragments, including staining of keratinizing cells or material within hair follicles of skin ( figure 2G ) and staining of the edges of striated muscle fibers ( figure 2H ). Similar to the previously published results for autopsied submandibular gland, 13 serous cell cytoplasmic staining was also observed in some cases and was considered to be nonspecific.
Minor salivary gland biopsy findings. All the minor salivary gland tissue fragments had relatively large amounts of glandular tissue present, as well as connective tissue. Total tissue volume ranged between 10 and 180 mm 3 and 21-106 stained slides were examined per subject. Only 1/15 cases had immunoreactive nerve fibers seen within both stroma and parenchyma (not shown). This subject was one of the subjects who had a positive submandibular gland biopsy.
Side effects. Side effects were minimal, with 5 patients having 1 adverse event each: swollen cheek, sore throat, excess fluid expelled from the needle biopsy site after a sneeze, swelling under the chin, and slight bleeding/swelling/bruising under the jaw.
DISCUSSION A tissue biopsy diagnostic test for PD could improve our current ability to treat patients and revolutionize how we perform and validate research studies for PD. To address the issue of an optimal peripheral biopsy site for PD, an extensive survey for LTS in the PNS of 41 tissue sites was performed. 12 As in previous studies, 22 the gastrointestinal (GI) tract contained LTS in most subjects with PD and there was a rostrocaudal gradient of GI LTS density, with the lower esophagus and submandibular gland having the highest densities and the colon and rectum the lowest. 12, 16, 23, 24 Prior to performing biopsies in living patients with PD, a postmortem submandibular gland study of 92 subjects with and without PD was performed. 13 Using immunohistochemical staining for phosphorylated a-synuclein, 17,25 both large blocks Tissue volume (mm 3 ) was calculated using the formula for volume of a cylinder. The total core tissue length (mm) was used as cylinder height while cylinder radius was calculated from the internal diameter of the needle, as supplied by the manufacturer. The maximum total cross-sectional area (mm 2 ) of microscopically identified submandibular gland area was measured using an ocular graticule under the microscope. The number of positive slides is the number that had positive phosphorylated a-synuclein-immunoreactive nerve elements present. Total slides is the total number of microscope slides stained and examined. The last column is the percentage of slides that were positive for phosphorylated a-synuclein-immunoreactive nerve elements.
(simulated open biopsy) and needle cores (simulated needle core biopsy) were assessed for LTS. The results showed high sensitivity (LTS in 28/28 PD cases) and specificity (only 3/22 patients with Alzheimer disease [AD] with Lewy bodies had submandibular gland LTS, while there was no positive staining in 5 subjects with incidental Lewy body disease, 2 with progressive supranuclear palsy, 3 with corticobasal degeneration, 2 with multiple system atrophy, 16 patients with AD without Lewy bodies, and 50 elderly control subjects). The next step in proof-of-concept for in vivo biopsies was a needle core biopsy of 19 of the postmortem PD submandibular glands, which found 17/19 (89.5%) were positive for LTS. Whereas this is a high positive rate, it also showed that needle core biopsies will miss some cases. 13 The present study was the first in vivo submandibular gland biopsy study and found LTS in 9 of 12 subjects with PD. If we assume, using published studies, 7-11 a clinical diagnostic accuracy rate (positive predictive value) of 85%, then 0.85 3 12 5 10 subjects in the present study would be likely to have autopsy-confirmed PD, suggesting our finding of 9/12 positive biopsies has high sensitivity. Additionally, as the postmortem needle biopsies of submandibular glands missed affected tissue, 13 the lack of 100% positivity is not surprising. While specificity was not assessed in this study as no control subjects or subjects with other parkinsonian disorders were included, results from Beach et al. 13 suggest that specificity for PD would be very high.
The initial difficulty with obtaining sufficient glandular tissue was largely rectified by using a larger caliber needle (16-gauge instead of 18-gauge), changing the trajectory of the needle insertion so that it was perpendicular to the gland's longitudinal axis, and taking more cores (4-5 instead of 1-2). Only 1 case out of 11 had no glandular tissue after the procedure was modified. Despite this success, ultrasound-guided biopsies may be considered in the future rather than just identifying the submandibular gland by palpation. At the present time, the amount of tissue sample needed to adequately find LTS is unclear, but the data suggest that at least 2 mm 2 on greatest cross-sectional area, or 8 mm 3 volumetrically, of microscopically identifiable salivary gland be used as a provisional definition.
In contrast to the submandibular gland biopsy results, the minor salivary gland biopsy was not sensitive for finding LTS, despite that fact that there was much more glandular tissue studied from the open minor salivary gland biopsies than from the submandibular gland needle cores. Although it was previously reported that 2/3 subjects with PD had positive LTS in minor salivary gland biopsies, 16 we found that only 1/15 cases were positive. This case also had a positive submandibular gland biopsy. After we had completed our study, another published study reported rare (3/16 PD cases with disease duration .8 years) LTS in minor salivary gland biopsies. 15 Weak positive staining was also found in 2 nonparkinsonian neurologic disease controls. 15 It is unclear why submandibular and minor salivary gland biopsy results differ. The parasympathetic innervation to both the submandibular gland and the labial minor salivary glands come from the lingual nerve, so this would not appear to be the cause. There are no published investigations of minor salivary gland tissue in autopsied PD cases so the presence of LTS in the minor salivary glands may not be a finding in PD. 15 Further use of minor salivary gland biopsies in PD is likely not warranted.
Another possible GI biopsy site is the colon. 26 Recent studies 5, [27] [28] [29] [30] have shown this is feasible but most of these studies required significant preprocedure preparation, sedation, general anesthesia, and more resources than the submandibular gland biopsy. 13, 27, 28 There also are conflicting data regarding the density of LTS in the submucosa of the colon as opposed to the myenteric plexus, and whether deeper layer biopsy into the muscular layer of the colon would be needed, which would increase risk to the patient and may be difficult to perform via a colonoscopy. 5, 22, 31, 32 A more recent study of unprepped flexible sigmoidoscopy is promising as an accessible site for outpatient tissue biopsy. 5 This study did not use phosphorylated a-synuclein and while staining was only found in PD cases and not in controls, further study is needed. 5 One clinical study and multiple autopsy studies suggest rectal biopsy would not be of value. 12, 22, 23, 29, 31, 33 The skin has also been investigated as a biomarker for PD; however, multiple studies have found minimal LTS in the skin. 6, 12 Other areas of biomarker development include assessing proteins in the CSF and saliva. However, no clear biomarker has been found. 1, 2, 4, 34, 35 Noninvasive biomarkers, while sensitive, do not have high enough specificity to be diagnostic. 36, 37 One limitation of this study was the selection of PD cases with disease duration of $5 years and responsiveness to dopaminergic medications (13 of the 15 cases had motor fluctuations). These selection criteria were used as they provided similar patient characteristics to the autopsy study 13 and this was to provide proof-ofconcept. It is clear that accuracy of the clinical diagnosis of PD improves in more advanced disease. [7] [8] [9] [10] [11] Depending on the criteria used for the diagnosis, many cases may not have a striatal dopaminergic deficit and many will have non-PD parkinsonism due to other neurodegenerative disorders such as progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration. Given the results in this study, future studies with patients with shorter disease duration will be important as having an accurate tissue diagnosis in patients with early PD would greatly increase the probability for successful clinical trials and provide tissue confirmation for other biomarker studies. In patients with more advanced PD, tissue confirmation by submandibular gland biopsy may be of potential use for selecting subjects for high-risk interventions such as deep brain stimulation, cell transplantation, and gene therapy. Additionally, tissue confirmation in patients with advanced PD would be valuable for other biomarker studies (genetic, CSF, saliva) that currently lack autopsy confirmation. An accurate tissue diagnosis for living patients with PD would therefore be of great benefit as a gold standard for confirming other biomarkers.
Another limitation of this study was the lack of control subjects. However, based on the autopsy study, 13 there was no evidence of LTS in 50 control subjects. This study also did not include subjects with other parkinsonian disorders, so determination of the specificity for LTS in submandibular gland biopsies for PD will require further study.
This study does provide proof-of-concept evidence for the feasibility of using submandibular gland biopsy as a sensitive tissue-based diagnostic test for the presence of LTS in living patients with clinically diagnosed PD. Submandibular gland biopsies were performed as outpatient procedures, used only local anesthetic, and were well-tolerated. Combined with the autopsy study, 13 the results suggest that submandibular gland biopsy may be a sensitive outpatient method to obtain tissue confirmation of LTS in PD. Future studies should include patients with early-stage PD, control subjects, subjects with other parkinsonian disorders, and, when possible, longitudinal studies extended to autopsy with neuropathologic confirmation of PD.
